Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (08) : 774-781     DOI: 10.3971/j.issn.1000-8578.2021.21.0221
Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA
YANG Tingfang1,2, WANG Li3, ZHANG Yong2
1. Graduate School of Kunming Medical University, Kunming 650500, China; 2. Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China; 3. Department of Pathology, The First People’s Hospital of Yunnan Province, Kunming 650032, China
Download: PDF(9041 KB)   ( 95 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the expression and prognostic value of FOXO1 gene in liver cancer tissues based on TCGA and HPA databases. Methods The RNA-seq data of FOXO1 gene in liver cancer were downloaded from TCGA. The difference of FOXO1 gene expression between tumor and adjacent tissues was obtained via R software. The correlation between FOXO1 and clinicopathological features of liver cancer patients was analyzed. Survival analysis was carried out to evaluate the prognostic significance of FOXO1 gene expression in liver cancer patients. Univariate and multivariate Cox analyses were performed to explore prognostic factors. The correlation between FOXO1 expression and TIICs in tumor microenvironment was performed by CIBERSORT. KEGG pathways enrichment analysis was performed for the potential function of FOXO1 gene in liver cancer. Results FOXO1 was downregulated in liver cancer tissues compared with normal tissues (P=1.321E-15). Survival analysis showed that high expression of FOXO1 was positively associated with favorable OS of liver cancer patients (P<0.05). Clinical stage, T and M stages could be prognostic indicators while FOXO1 wasn’t an independent prognostic factor in patients with liver cancer. In TME of liver cancer, the expression of FOXO1 was positively correlated with resting memory CD4 T cells and naive B cells while negatively related to activated memory CD4 T cells and macrophages M2. GSEA identified that FOXO1 participated in multiple cancer-related pathways. Conclusion FOXO1 is down-regulated in liver cancer tissues, and its expression level is associated with OS of patients. FOXO1 might be a biomarker related to the prognosis of liver cancer patients and is expected to be a target for diagnosis and treatment of liver cancer.
Keywords FOXO1      Liver cancer      TCGA     
ZTFLH:  R735.7  
Fund:National Natural Science Foundation of China (No. 81860557)
Issue Date: 18 August 2021
 Cite this article:   
YANG Tingfang,WANG Li,ZHANG Yong. Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA[J]. Cancer Research on Prevention and Treatment, 2021, 48(08): 774-781.
E-mail this article
E-mail Alert
Articles by authors
YANG Tingfang
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):
[2] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk
factors in China and its provinces, 1990-2017: a systematic
analysis for the Global Burden of Disease Study 2017[J]. Lancet,
2019, 394(10204): 1145-1158.
[3] Llovet JM, Montal R, Villanueva A. Randomized trials and
endpoints in advanced HCC: Role of PFS as a surrogate of
survival[J]. J Hepatol, 2019, 70(6): 1262-1277.
[4] Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular
carcinoma: implications for genomic and immune therapies[J].
Mol Cancer, 2017, 16(1): 149.
[5] Sia D, Villanueva A, Friedman SL, et al. Liver Cancer Cell of
Origin, Molecular Class, and Effects on Patient Prognosis[J].
Gastroenterology, 2017, 152(4): 745-761.
[6] Qiu Z, Li H, Zhang Z, et al. A Pharmacogenomic Landscape in
Human Liver Cancers[J]. Cancer Cell, 2019, 36(2): 179-193.
[7] Kim CG, Lee H, Gupta N, et al. Role of Forkhead Box Class Oproteins in cancer progression and metastasis[J]. Semin Cancer Biol, 2018, 50:142-151.
[8] Shi F, Li T, Liu Z, et al. FOXO1: Another avenue for treating
digestive malignancy?[J]. Semin Cancer Biol, 2018, 50: 124-131.
[9] Gryder BE, Yohe ME, Chou HC, et al. PAX3-FOXO1 Establishes
Myogenic Super Enhancers and Confers BET Bromodomain
Vulnerability[J]. Cancer Discov, 2017, 7(8): 884-899.
[10] Yu JM, Sun W, Wang ZH, et al. TRIB3 supports breast cancer
stemness by suppressing FOXO1 degradation and enhancing
SOX2 transcription[J]. Nat Commun, 2019, 10(1): 5720.
[11] Han GH, Chay DB, Nam S, et al. Prognostic implications of
forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in
epithelial ovarian cancer[J]. BMC Cancer, 2019, 19(1): 1202.
[12] Chae YC, Kim JY, Park JW, et al. FOXO1 degradation via
G9a-mediated methylation promotes cell proliferation in colon
cancer[J]. Nucleic Acids Res, 2019, 47(4): 1692-1705.
[13] Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2
transcriptional activity and prostate cancer cell migration and
invasion[J]. Cancer Res, 2011, 71(9): 3257-3267.
[14] 汤庆. 原发性肝癌发病年轻化的原因分析[J]. 世界最新医学信
息文摘, 2015, 15(53): 95. [Tang Q. Analysis of the causes of the
younger trend incidence of primary liver cancer[J]. Shijie Zui Xin
Yi Xue Xin Xi Wen Zhai, 2015, 15(53): 95.]
[15] Llovet JM, Montal R, Sia D, et al. Molecular therapies and
precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin
Oncol, 2018, 15(10): 599-616.
[16] Alharbi MA, Zhang C, Lu C, et al. FOXO1 Deletion Reverses
the Effect of Diabetic-Induced Impaired Fracture Healing[J].
Diabetes, 2018, 67(12): 2682-2694.
[17] Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic
gluconeogenesis through FOXO1-PGC-1alpha interaction[J].
Nature, 2003, 423(6939): 550-555.
[18] Chi HC, Chen SL, Cheng YH, et al. Chemotherapy resistance
and metastasis-promoting effects of thyroid hormone in
hepatocarcinoma cells are mediated by suppression of FOXO1
and Bim pathway[J]. Cell Death Dis, 2016, 7(8): e2324.
[19] Calvisi DF, Ladu S, Pinna F, et al. SKP2 and CKS1 promote
degradation of cell cycle regulators and are associated with
hepatocellular carcinoma prognosis[J]. Gastroenterology, 2009,
137(5): 1816-1826.
[20] J i a n g T Y, P a n Y F, Wa n Z H , e t a l . P T EN s t a t u s
determines chemosensitivity to proteasome inhibition in
cholangiocarcinoma[J]. Sci Transl Med, 2020, 12(562): eaay0152.
[21] Frampton G, Ueno Y, Quinn M, et al. The novel growth factor,
progranulin, stimulates mouse cholangiocyte proliferation via
sirtuin-1-mediated inactivation of FOXO1[J]. Am J Physiol
Gastrointest Liver Physiol, 2012, 303(11): G1202-G1211.
[22] Wang Y, Lyu Z, Qin Y, et al. FOXO1 promotes tumor progression
by increased M2 macrophage infiltration in esophageal squamous
cell carcinoma[J]. Theranostics, 2020, 10(25): 11535-11548.
[23] Zheng CH, Zheng, LT, Yoo JK, et al. Landscape of Infiltrating T
Cells in Liver Cancer Revealed by Single-Cell Sequencing[J].
Cell, 2017, 169(7): 1342-1356. e16.
[24] Zhang Z, Ma L, Goswami S, et al. Landscape of infiltrating
B cells and their clinical significance in human hepatocellular
carcinoma[J]. Oncoimmunology, 2019, 8(4): e1571388.
[25] Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating
lymphocyte grade is an independent predictor of sentinel lymph
node status and survival in patients with cutaneous melanoma[J].
J Clin Oncol, 2012, 30(21): 2678-2683.
[26] Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, et al.
Deviations of the immune cell landscape between healthy liver
and hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 6220.
[27] Trinité B, Chan CN, Lee CS, et al. Suppression of Foxo1 activity
and down-modulation of CD62L (L-selectin) in HIV-1 infected
resting CD4 T cells[J]. PLoS One, 2014, 9(10): e110719.
[28] Cafri G, Yossef R, Pasetto A, et al. Memory T cells targeting
oncogenic mutations detected in peripheral blood of epithelial
cancer patients[J]. Nat Commun, 2019, 10(1): 449.

Related articles from Frontiers Journals
[1] WANG Zhihui, ZHANG Shuijun. Influence of Multidisciplinary Combined Therapy on Curative Effect of Liver Cancer Treatment[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 880-885.
[2] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[3] LI Menghan, XIAO Qiong, GAO Peng, FU Yu, SUN Chenrui, SONG Yongxi. LncRNA Prognostic Risk Scoring Model for Gastrointestinal Tumors Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 606-611.
[4] GAO Haining, BAI Ruixia, ZHAO Pengwei, SONG Wanying, LIN Xuan. Effect of miR-581 on Autophagy of Ovarian Cancer SKOV3 Cells by Regulating FOXO1[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 403-407.
[5] LIU Changjian, WANG Jian, LIU Shaoyan. Pyroptosis-related lncRNAs Predict Prognosis of Laryngeal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 335-339.
[6] LI Shenghao, SHI Xinli. Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1052-1058.
[7] YANG Xi, CHU Yaojuan, CHEN Juanjuan, YANG Ting, LIU Chong, ZHANG Rui, DU Shuzhang. Visual Analysis and Focused Areas of Immunotherapy for Liver Cancer Based on Literature Data[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 963-969.
[8] KE Shaobo, WANG Jing, QIU Hu, CAI Gaoke, GONG Yi, CHEN Yongshun. Therapeutic Effect of Apatinib in First-line Treatment of Advanced Liver Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 723-726.
[9] XIAO Huijuan, ZHANG Ming, QI Yumei, HAN Tao, WANG Xin. Relation of Phase Angle with Nutritional Status and Clinical Outcomes of Primary Liver Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 503-507.
[10] QI Xiaoguang, QI Chunyan, QIN Boyu, HU Yi, HAN Weidong. Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 839-845.
[11] WU Juan, ZHANG Yaqin, WU Yunbin, CHEN Min, YU Zhou, CAO Yingping. Clinical Value of S-poly (T) plus Real-time PCR in Detection of Liver Cancer-related miR-199[J]. Cancer Research on Prevention and Treatment, 2020, 47(10): 761-765.
[12] LI Bo, LYU Ming, ZHOU Shuai. Expression and Clinical Significance of lnc RNA HOXA11-AS in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(08): 607-610.
[13] JIAO Zhaoshuang, ZHANG Huainian. Establishment and Analysis of MicroRNA Prognostic Risk Model of Papillary Thyroid Carcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2020, 47(04): 262-267.
[14] JIAN Yaowen, WANG Lei, LIU Ye, HE Mingyan, RANG Weiqing. A Meta-analysis of Dietary Vitamin Consumption and Risk of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(02): 108-111.
[15] ZHU Yaling, YI Fengtao, DING Mengnan, ZENG Cheng, XU Zhenhua, SHAO Zhixiong, XIE Junjie. Secretory Function of Kupffer Cells in Liver Cancer After Cryoablation[J]. Cancer Research on Prevention and Treatment, 2020, 47(01): 20-24.
Full text